Andy_D

MSB gets Fast Track from FDA

Long
ASX:MSB   MESOBLAST LIMITED
Looks like price is respecting trendline / uptrend.

Price is within range. Needs to break above resistance and stay above for bullish confirmation.

Next target I would imagine a sell off unless FDA approval or some super bullish news is released and it gaps up (possible with these lower cap stocks).

Overall lots of bullish news, Novartis partnership + FDA Fast Track for Remestemcell-L
Comment: Sadly bad news came out and the trend was invalidated - trading just above 78.6% area. I'm in quite a rough drawdown on my positions but you live and you learn. Biotcech stocks are highly risky!

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.